These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19422092)

  • 21. NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.
    Brady LS; Winsky L; Goodman W; Oliveri ME; Stover E
    Neuropsychopharmacology; 2009 Jan; 34(1):229-43. PubMed ID: 18800066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Making translation work.
    Williams RS; Desmond-Hellmann S
    Science; 2011 Jun; 332(6036):1359. PubMed ID: 21680815
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Public-private partnerships need honest brokering.
    Goldman M
    Nat Med; 2012 Mar; 18(3):341. PubMed ID: 22395691
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacotherapy crisis in the spotlight--is open collaboration between academia and industry the answer?
    Kaski JC
    Cardiovasc Drugs Ther; 2011 Apr; 25(2):187-8. PubMed ID: 21503624
    [No Abstract]   [Full Text] [Related]  

  • 26. Playing well with others! Initiating and sustaining successful collaborations between industry, academia and government.
    Thomas CJ; McKew JC
    Curr Top Med Chem; 2014; 14(3):291-3. PubMed ID: 24283974
    [No Abstract]   [Full Text] [Related]  

  • 27. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Into the valley of death: research to innovation.
    Hudson J; Khazragui HF
    Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New and evolving rare diseases research programs at the National Institutes of Health.
    Groft SC; Rubinstein YR
    Public Health Genomics; 2013; 16(6):259-67. PubMed ID: 24503586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 31. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Data sharing: Access all areas.
    Owens B
    Nature; 2016 May; 533(7602):S71-2. PubMed ID: 27167398
    [No Abstract]   [Full Text] [Related]  

  • 33. Managing intellectual property to develop medicines for the world's poorest.
    Fonteilles-Drabek S; Reddy D; Wells TN
    Nat Rev Drug Discov; 2017 Apr; 16(4):223-224. PubMed ID: 28232725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Consideration on Academia Environments for Creating Medical Innovation].
    Iida K; Ishida T; Nishimura N
    Yakugaku Zasshi; 2022 Jan; 142(1):75-84. PubMed ID: 34629350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global strategic partnerships in regenerative medicine.
    French A; Suh JY; Suh CY; Rubin L; Barker R; Bure K; Reeve B; Brindley DA
    Trends Biotechnol; 2014 Sep; 32(9):436-40. PubMed ID: 25150363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spat over IMI funding and intellectual property.
    Sinha G
    Nat Biotechnol; 2011 Jun; 29(6):473. PubMed ID: 21654659
    [No Abstract]   [Full Text] [Related]  

  • 37. Europe bets on drug discovery.
    Baker M
    Nature; 2013 Feb; 494(7435):20. PubMed ID: 23393658
    [No Abstract]   [Full Text] [Related]  

  • 38. [Development of synergies and partnerships on rare diseases: model of a scientific cooperation foundation].
    Lévy N
    Presse Med; 2012 May; 41 Suppl 1():S23-5. PubMed ID: 22483766
    [No Abstract]   [Full Text] [Related]  

  • 39. Yale Center for Clinical Investigation: leveraging industry partnerships and research cores.
    Sherwin R; Slayman C; Rockwell S; Herold K; Williams K; Carson R; Mane S; Seow H; Max J; Johnson T
    Clin Transl Sci; 2012 Dec; 5(6):435-6. PubMed ID: 23253663
    [No Abstract]   [Full Text] [Related]  

  • 40. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
    Chung TD
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.